R. Bernardini

Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.

G. Pezzoni, B. Ruggeri, J. Mallamo, 2008, Journal of medicinal chemistry.

Stability of Boronic Esters to Hydrolysis : A Comparative Study

L. Goldoni, E. Menta, R. Bernardini, 2009 .

Overall view of the use of chiral platinum(II) complexes as chiral derivatizing agents (CDAs) for the enantiodiscrimination of unsaturated compounds by 195Pt NMR.

P. Salvadori, G. Uccello-Barretta, F. Balzano, 2002, Chirality.

[PtCl3(C2H4)]-[(S,S)-(PhMeCH)2NH2]+: A new and versatile ionic organometallic chiral derivatizing agent for the determination of the enantiomeric composition of chiral unsaturated compounds by 195Pt NMR spectroscopy

P. Salvadori, G. Uccello-Barretta, R. Bernardini, 2000 .

Use of cis-dichloro[(S)-α-methylbenzylamine](ethylene)Pt(II) as a chiral derivatizing agent for the determination by 195Pt-NMR of the enantiomeric composition of unsaturated ethers or alcohols having a quaternary chiral carbon atom

R. Lazzaroni, P. Salvadori, G. Uccello-Barretta, 2000 .

On the high efficiency of cis-dichloro[(S)-α-methylbenzylamine](ethylene)platinum(II) as chiral derivatizing agent for the determination of the enantiomeric composition of chiral unsaturated ethers by 195Pt-NMR spectroscopy: a spectroscopic conformational and configurational characterization in solu

R. Lazzaroni, P. Salvadori, G. Uccello-Barretta, 2000 .

Cucurbit[7]uril Inclusion Complexes of Platinum(II)-based Anticancer Drugs: Further Insight

L. Goldoni, M. Cassin, R. Bernardini, 2010 .